Cancer Therapy Market Synopsis:
Cancer Therapy Market Size Was Valued at USD 178.2 Billion in 2023 and is Projected to Reach USD 393.6 Billion by 2032, Growing at a CAGR of 9.2% From 2024-2032.
The Cancer therapy market encompasses range of treatments and medications designed to handle and remove cancerous cells in the human organism. This market belongs to chemotherapy, immunotherapy, radiotherapy, hormonal therapy and target therapy that play important roles in enhancing patient prognosis and survival ratio. These therapies are meant to be targeted at cancer cells only, control the progression of disease, and slow the growth of tumors. By following the progress of medical science and adding individual methods of treatment to cancer therapy the market is seen as a part of the medical system that can help millions of people in their fight against cancer.
The cancer therapy has faced consistent demand across the world due to rising incidences of cancer and patients’ awareness over early detection of diseases. Increasing affordability of cancer related products and services along detailed Targeted Treatment for Cancer Research efforts started by the government and private players also require the development of effective and cheap cancer therapies. Thirdly, the advancement in the drug and diagnostics also paved way to the use of new treatment methods through improvement of the cancer care through appropriate technologies.
The identified key therapeutic areas within the patient group of the global market of cancer therapy include chemotherapy, immunotherapy, and radiation therapy. Immunotherapy in particular has received significant attention because through it cancer cells can be destroyed while the normal cells undergo minimal damage hence reducing on side effects of treatments. Despite this, chemotherapy is still common and with the advancements in targeted therapies, we now have offered various treatment strategies to match with the kind of cancer. The cancer therapy market is swiftly progressing due to the growing demand for the development of advanced treatments for cancer, a sufficient number of drugs in the pharmaceutical pipeline, and a fast-developing healthcare system in the future years.
Cancer Therapy Market Trend Analysis:
Rise of Personalized Cancer Therapy
- Molecular cancer therapy or target therapy is a current development that has revolutionized the way cancer is being treated it prospect a more hopeful way of attacking the disease. It involves developing individualistic treatments based on the genes of individual patients in order that the providers can attack cancer cells more accurately without damaging normal cells in the same process. This approach has led to the development of therapies for example the CAR T-cell therapy a treatment that involves doctors using a patient’s cells to attack cancer. Some of the effects of this innovation have been; the general enhancement of the outcomes of treatment plans; and the minimisation of the side effects experienced by patients.
- Genomic testing has emerged in the recent past as a vital aspect to boost the growth of personalized cancer treatments and analysis of using AI in healthcare. Depending on biomarker analysis these therapies can potentially transform cancer treatment into much more targeted approach that allows doctors to choose treatment options that would be most effective in each case given patient’s characteristics. This trend steadily increases annually, and as the popularity of this approach to cancer therapy increases, it will become one of the main drivers not only of revenue growth for the oncology industry, but also of pharmaceutical companies’ interest in this new segment.
Expanding Access in Emerging Markets
- A considerable share of the potential customers, especially in the sphere of cancer therapy, can be found in emerging markets as they have always had systemic problems with cancer treatment. The increase in the number of persons getting cancer in various countries particularly in Asia-Pacific, Latin America, and Africa is attributable to; pollution, changes in diet and the growing proportion of the aged. However, they represented only approximately 25% of the population, and healthcare infrastructure and access to advanced treatments in these regions are still very limited, thereby implying a huge gap in the offer of the cancer care services. As these countries continue to receive more global investments from both government and private institutions, most of these emerging economies have=’s on funding the growth of cancer care centers. The governments and the health care organizations of these countries are also realizing the opportunity and all the large pharma majors are on the move to spread into such countries by providing cheap cure and in partnership with the local health care systems.
Cancer Therapy Market Segment Analysis:
Cancer Therapy Market is Segmented on the basis of Type, Cancer Type, End User, and Region
By Type, Chemotherapy segment is expected to dominate the market during the forecast period
- There are segmentations in cancer therapy market, where the chemotherapy segment is forecasted to have the largest demand over the forecast period because of its traditional efficiency in treating many forms of cancer. Chemotherapy is fundamental therapy still used in different health care facilities all over the world because it targets and kills fast dividing cancer cells. Even though new targeted therapies and immunotherapies have emerged, chemotherapy remains an important choice because the new therapies can be ineffective or unavailable in some forms. Further, the ongoing research conducted with an objective to make chemotherapy drugs more effective and non-hazardous along with the integration of these drugs with other treatments has further enhanced the position of chemotherapy market. A vast availability of proper methods for administration of chemotherapy and their well-developed infrastructure can be considered as the major factors that strengthen the expected chemotherapy’s leaders in the rating of the market during the forecast period.
By Cancer Type, Blood Cancer segment expected to held the largest share
- The blood cancer is also expected to dominate the market since the cancer therapy as leukaemia, lymphoma and multiple myeloma has been on the rise across the world and also due to availability of better treatment solutions. Blood cancer is one of the most lethal and hardest-to-treat types of cancer, so there is an immense interest in therapies, chemotherapy, and immunotherapy focused on the treatment of these cancers. CAR T cell therapy, and other immunotherapies, have delivered long-lasting and personalised treatments for blood cancer patients and are some of the factors that have boosted the segment. Furthermore, a more focused approach on the early diagnostics and a large share of research funding has pushed the adoption of improved treatments, and so blood cancer remains the most developed segment of the cancer therapy market.
Cancer Therapy Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
- North America especially the United States holds the highest share within the global cancer therapy market owing to effective health care provisions, research and development activities and premier pharmaceutical companies. According to market statistics, in 2023 North America had approximately 40% of the whole worldwide market owing to factors such as technological development and early implementation of the progressing treatments like immunotherapy and precision medicine. The emphasis on prevention, including the diagnosis of cancer at early stages, has resulted in high demand for cancer treatment in the region: North America is ahead of all other markets.
Active Key Players in the Cancer Therapy Market:
- AbbVie (USA)
- Amgen (USA)
- AstraZeneca (UK)
- Bayer (Germany)
- Bristol-Myers Squibb (USA)
- Eli Lilly and Company (USA)
- Gilead Sciences (USA)
- GlaxoSmithKline (UK)
- Johnson & Johnson (USA)
- Merck & Co. (USA)
- Novartis (Switzerland)
- Pfizer (USA)
- Roche (Switzerland)
- Sanofi (France)
- Takeda Pharmaceutical (Japan)
- Other Active Players
|
Cancer Therapy Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 194.6 Billion |
|
Forecast Period 2024-32 CAGR: |
9.2 % |
Market Size in 2032: |
USD 393.6 Billion |
|
Segments Covered: |
By Type |
|
|
|
By Cancer Type |
|
||
|
By End User |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Cancer Therapy Market by By Type (2018-2032)
4.1 Cancer Therapy Market Snapshot and Growth Engine
4.2 Market Overview
4.3 Chemotherapy
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
4.3.3 Key Market Trends, Growth Factors, and Opportunities
4.3.4 Geographic Segmentation Analysis
4.4 Target Therapy
4.5 Immunotherapy
4.6 Radiotherapy
4.7 Others
Chapter 5: Cancer Therapy Market by By Cancer Type (2018-2032)
5.1 Cancer Therapy Market Snapshot and Growth Engine
5.2 Market Overview
5.3 Blood Cancer
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
5.3.3 Key Market Trends, Growth Factors, and Opportunities
5.3.4 Geographic Segmentation Analysis
5.4 Lung Cancer
5.5 Colorectal Cancer
5.6 Prostate Cancer
5.7 Breast Cancer
5.8 Cervical Cancer
5.9 Head and Neck Cancer
5.10 Glioblastoma
5.11 Malignant Meningioma
5.12 Mesothelioma
5.13 Others
Chapter 6: Cancer Therapy Market by By End User (2018-2032)
6.1 Cancer Therapy Market Snapshot and Growth Engine
6.2 Market Overview
6.3 Hospitals
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
6.3.3 Key Market Trends, Growth Factors, and Opportunities
6.3.4 Geographic Segmentation Analysis
6.4 Specialty Clinics
6.5 Cancer and Radiation Therapy Centers
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Benchmarking
7.1.2 Cancer Therapy Market Share by Manufacturer (2024)
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Mergers and Acquisitions
7.2 ABBVIE (USA)
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Role of the Company in the Market
7.2.5 Sustainability and Social Responsibility
7.2.6 Operating Business Segments
7.2.7 Product Portfolio
7.2.8 Business Performance
7.2.9 Key Strategic Moves and Recent Developments
7.2.10 SWOT Analysis
7.3 AMGEN (USA)
7.4 ASTRAZENECA (UK)
7.5 BAYER (GERMANY)
7.6 BRISTOL-MYERS SQUIBB (USA)
7.7 ELI LILLY AND COMPANY (USA)
7.8 GILEAD SCIENCES (USA)
7.9 GLAXOSMITHKLINE (UK)
7.10 JOHNSON & JOHNSON (USA)
7.11 MERCK & CO. (USA)
7.12 NOVARTIS (SWITZERLAND)
7.13 PFIZER (USA)
7.14 ROCHE (SWITZERLAND)
7.15 SANOFI (FRANCE)
7.16 TAKEDA PHARMACEUTICAL (JAPAN)
7.17 OTHER ACTIVE PLAYERS
Chapter 8: Global Cancer Therapy Market By Region
8.1 Overview
8.2. North America Cancer Therapy Market
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Top Key Companies
8.2.3 Historic and Forecasted Market Size by Segments
8.2.4 Historic and Forecasted Market Size By By Type
8.2.4.1 Chemotherapy
8.2.4.2 Target Therapy
8.2.4.3 Immunotherapy
8.2.4.4 Radiotherapy
8.2.4.5 Others
8.2.5 Historic and Forecasted Market Size By By Cancer Type
8.2.5.1 Blood Cancer
8.2.5.2 Lung Cancer
8.2.5.3 Colorectal Cancer
8.2.5.4 Prostate Cancer
8.2.5.5 Breast Cancer
8.2.5.6 Cervical Cancer
8.2.5.7 Head and Neck Cancer
8.2.5.8 Glioblastoma
8.2.5.9 Malignant Meningioma
8.2.5.10 Mesothelioma
8.2.5.11 Others
8.2.6 Historic and Forecasted Market Size By By End User
8.2.6.1 Hospitals
8.2.6.2 Specialty Clinics
8.2.6.3 Cancer and Radiation Therapy Centers
8.2.7 Historic and Forecast Market Size by Country
8.2.7.1 US
8.2.7.2 Canada
8.2.7.3 Mexico
8.3. Eastern Europe Cancer Therapy Market
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Top Key Companies
8.3.3 Historic and Forecasted Market Size by Segments
8.3.4 Historic and Forecasted Market Size By By Type
8.3.4.1 Chemotherapy
8.3.4.2 Target Therapy
8.3.4.3 Immunotherapy
8.3.4.4 Radiotherapy
8.3.4.5 Others
8.3.5 Historic and Forecasted Market Size By By Cancer Type
8.3.5.1 Blood Cancer
8.3.5.2 Lung Cancer
8.3.5.3 Colorectal Cancer
8.3.5.4 Prostate Cancer
8.3.5.5 Breast Cancer
8.3.5.6 Cervical Cancer
8.3.5.7 Head and Neck Cancer
8.3.5.8 Glioblastoma
8.3.5.9 Malignant Meningioma
8.3.5.10 Mesothelioma
8.3.5.11 Others
8.3.6 Historic and Forecasted Market Size By By End User
8.3.6.1 Hospitals
8.3.6.2 Specialty Clinics
8.3.6.3 Cancer and Radiation Therapy Centers
8.3.7 Historic and Forecast Market Size by Country
8.3.7.1 Russia
8.3.7.2 Bulgaria
8.3.7.3 The Czech Republic
8.3.7.4 Hungary
8.3.7.5 Poland
8.3.7.6 Romania
8.3.7.7 Rest of Eastern Europe
8.4. Western Europe Cancer Therapy Market
8.4.1 Key Market Trends, Growth Factors and Opportunities
8.4.2 Top Key Companies
8.4.3 Historic and Forecasted Market Size by Segments
8.4.4 Historic and Forecasted Market Size By By Type
8.4.4.1 Chemotherapy
8.4.4.2 Target Therapy
8.4.4.3 Immunotherapy
8.4.4.4 Radiotherapy
8.4.4.5 Others
8.4.5 Historic and Forecasted Market Size By By Cancer Type
8.4.5.1 Blood Cancer
8.4.5.2 Lung Cancer
8.4.5.3 Colorectal Cancer
8.4.5.4 Prostate Cancer
8.4.5.5 Breast Cancer
8.4.5.6 Cervical Cancer
8.4.5.7 Head and Neck Cancer
8.4.5.8 Glioblastoma
8.4.5.9 Malignant Meningioma
8.4.5.10 Mesothelioma
8.4.5.11 Others
8.4.6 Historic and Forecasted Market Size By By End User
8.4.6.1 Hospitals
8.4.6.2 Specialty Clinics
8.4.6.3 Cancer and Radiation Therapy Centers
8.4.7 Historic and Forecast Market Size by Country
8.4.7.1 Germany
8.4.7.2 UK
8.4.7.3 France
8.4.7.4 The Netherlands
8.4.7.5 Italy
8.4.7.6 Spain
8.4.7.7 Rest of Western Europe
8.5. Asia Pacific Cancer Therapy Market
8.5.1 Key Market Trends, Growth Factors and Opportunities
8.5.2 Top Key Companies
8.5.3 Historic and Forecasted Market Size by Segments
8.5.4 Historic and Forecasted Market Size By By Type
8.5.4.1 Chemotherapy
8.5.4.2 Target Therapy
8.5.4.3 Immunotherapy
8.5.4.4 Radiotherapy
8.5.4.5 Others
8.5.5 Historic and Forecasted Market Size By By Cancer Type
8.5.5.1 Blood Cancer
8.5.5.2 Lung Cancer
8.5.5.3 Colorectal Cancer
8.5.5.4 Prostate Cancer
8.5.5.5 Breast Cancer
8.5.5.6 Cervical Cancer
8.5.5.7 Head and Neck Cancer
8.5.5.8 Glioblastoma
8.5.5.9 Malignant Meningioma
8.5.5.10 Mesothelioma
8.5.5.11 Others
8.5.6 Historic and Forecasted Market Size By By End User
8.5.6.1 Hospitals
8.5.6.2 Specialty Clinics
8.5.6.3 Cancer and Radiation Therapy Centers
8.5.7 Historic and Forecast Market Size by Country
8.5.7.1 China
8.5.7.2 India
8.5.7.3 Japan
8.5.7.4 South Korea
8.5.7.5 Malaysia
8.5.7.6 Thailand
8.5.7.7 Vietnam
8.5.7.8 The Philippines
8.5.7.9 Australia
8.5.7.10 New Zealand
8.5.7.11 Rest of APAC
8.6. Middle East & Africa Cancer Therapy Market
8.6.1 Key Market Trends, Growth Factors and Opportunities
8.6.2 Top Key Companies
8.6.3 Historic and Forecasted Market Size by Segments
8.6.4 Historic and Forecasted Market Size By By Type
8.6.4.1 Chemotherapy
8.6.4.2 Target Therapy
8.6.4.3 Immunotherapy
8.6.4.4 Radiotherapy
8.6.4.5 Others
8.6.5 Historic and Forecasted Market Size By By Cancer Type
8.6.5.1 Blood Cancer
8.6.5.2 Lung Cancer
8.6.5.3 Colorectal Cancer
8.6.5.4 Prostate Cancer
8.6.5.5 Breast Cancer
8.6.5.6 Cervical Cancer
8.6.5.7 Head and Neck Cancer
8.6.5.8 Glioblastoma
8.6.5.9 Malignant Meningioma
8.6.5.10 Mesothelioma
8.6.5.11 Others
8.6.6 Historic and Forecasted Market Size By By End User
8.6.6.1 Hospitals
8.6.6.2 Specialty Clinics
8.6.6.3 Cancer and Radiation Therapy Centers
8.6.7 Historic and Forecast Market Size by Country
8.6.7.1 Turkiye
8.6.7.2 Bahrain
8.6.7.3 Kuwait
8.6.7.4 Saudi Arabia
8.6.7.5 Qatar
8.6.7.6 UAE
8.6.7.7 Israel
8.6.7.8 South Africa
8.7. South America Cancer Therapy Market
8.7.1 Key Market Trends, Growth Factors and Opportunities
8.7.2 Top Key Companies
8.7.3 Historic and Forecasted Market Size by Segments
8.7.4 Historic and Forecasted Market Size By By Type
8.7.4.1 Chemotherapy
8.7.4.2 Target Therapy
8.7.4.3 Immunotherapy
8.7.4.4 Radiotherapy
8.7.4.5 Others
8.7.5 Historic and Forecasted Market Size By By Cancer Type
8.7.5.1 Blood Cancer
8.7.5.2 Lung Cancer
8.7.5.3 Colorectal Cancer
8.7.5.4 Prostate Cancer
8.7.5.5 Breast Cancer
8.7.5.6 Cervical Cancer
8.7.5.7 Head and Neck Cancer
8.7.5.8 Glioblastoma
8.7.5.9 Malignant Meningioma
8.7.5.10 Mesothelioma
8.7.5.11 Others
8.7.6 Historic and Forecasted Market Size By By End User
8.7.6.1 Hospitals
8.7.6.2 Specialty Clinics
8.7.6.3 Cancer and Radiation Therapy Centers
8.7.7 Historic and Forecast Market Size by Country
8.7.7.1 Brazil
8.7.7.2 Argentina
8.7.7.3 Rest of SA
Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
|
Cancer Therapy Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 194.6 Billion |
|
Forecast Period 2024-32 CAGR: |
9.2 % |
Market Size in 2032: |
USD 393.6 Billion |
|
Segments Covered: |
By Type |
|
|
|
By Cancer Type |
|
||
|
By End User |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Frequently Asked Questions :
The forecast period in the Cancer Therapy Market research report is 2024-2032.
AbbVie (USA), Amgen (USA), AstraZeneca (UK), Bayer (Germany), Bristol-Myers Squibb (USA), Eli Lilly and Company (USA), Gilead Sciences (USA), GlaxoSmithKline (UK), Johnson & Johnson (USA), Merck & Co. (USA), Novartis (Switzerland), Pfizer (USA), Roche (Switzerland), Sanofi (France), Takeda Pharmaceutical (Japan), and Other Active Players.
The Cancer Therapy Market is segmented into Type, Cancer Type, End User and region. By Type, the market is categorized into Chemotherapy, Target Therapy, Immunotherapy, Radiotherapy, and Others. By Application, the market is categorized into Blood Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head and Neck Cancer, Glioblastoma, Malignant Meningioma, Mesothelioma, Others. By End User, the market is categorized into Hospitals, Specialty Clinics, Cancer and Radiation Therapy Centers. By region, it is analyzed across North America (U.S., Canada, Mexico), Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe), Western Europe (Germany, UK, France, The Netherlands, Italy, Spain, Rest of Western Europe), Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC), Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa), South America (Brazil, Argentina, Rest of SA)
The Cancer therapy market encompasses ood range of treatments and medications designed to handle and remove cancerous cells in the human organism. This market belongs to chemotherapy, immunotherapy, radiotherapy, hormonal therapy and target therapy that play important roles in enhancing patient prognosis and survival ratio. These therapies are meant to be targeted at cancer cells only, control the progression of disease, and slow the growth of tumors. By following the progress of medical science and adding individual methods of treatment to cancer therapy the market is seen as a part of the medical system that can help millions of people in their fight against cancer.
Cancer Therapy Market Size Was Valued at USD 178.2 Billion in 2023, and is Projected to Reach USD 393.6 Billion by 2032, Growing at a CAGR of 9.2% From 2024-2032.
